
Pedro Barata

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11374881/publications.pdf Version: 2024-02-01



<u> Ρεήρο Βλρλτλ</u>

#	Article	IF	CITATIONS
1	Association of prior local therapy and outcomes with programmedâ€death ligandâ€1 inhibitors in advanced urothelial cancer. BJU International, 2022, 130, 592-603.	1.3	3
2	Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin. Clinical Genitourinary Cancer, 2022, 20, 165-175.	0.9	4
3	Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer, 2022, 20, e440-e452.	0.9	10
4	Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. BJU International, 2021, 128, 196-205.	1.3	18
5	Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer. Prostate, 2021, 81, 433-439.	1.2	29
6	A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. European Urology Oncology, 2021, 4, 464-472.	2.6	39
7	Clinical Outcomes of Platinum-ineligible Patients with Advanced Urothelial Carcinoma Treated With First-line PD1/L1 Inhibitors. Clinical Genitourinary Cancer, 2021, 19, 425-433.	0.9	15
8	Impact of performance status on treatment outcomes: A realâ€world study of advanced urothelial cancer treated with immune checkpoint inhibitors. Cancer, 2020, 126, 1208-1216.	2.0	70
9	Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study. Journal of Urology, 2020, 204, 63-70.	0.2	32